The University of Southampton
University of Southampton Institutional Repository

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE Single Technology Appraisal

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE Single Technology Appraisal
Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE Single Technology Appraisal

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer (The Medicines Company) of bivalirudin to submit evidence for its clinical and cost effectiveness within its licensed indication for the treatment of adults with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PPCI), as part of NICE's single technology appraisal (STA) process. The School of Health and Related Research (ScHARR) at the University of Sheffield was commissioned to act as the Evidence Review Group (ERG), which produced a review of the evidence within the manufacturer's submission to NICE. This article describes the manufacturer's submission, the ERG review and NICE's subsequent decisions. The main evidence was derived from one randomized controlled trial (RCT) of STEMI patients intended for PPCI, comparing bivalirudin with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors (GPIs). Bivalirudin was associated with a significant reduction in cardiac mortality at 30 days (p = 0.03) and at 1-year follow-up (p = 0.005), and a significant reduction in major bleeding at 30 days (p < 0.001) and 1 year (p < 0.0001), compared with heparin plus GPI. Stent thrombosis up to 24 hours following PPCI was significantly (p < 0.001) more common with bivalirudin. However, there was no significant treatment effect for stent thrombosis from 1 to 30 days (p = 0.28), or at 1-year follow-up (p = 0.53). There were no significant treatment group differences at 30 days and at 1 year in stroke (p = 0.68 and p = 0.99, respectively), in myocardial infarction [MI] (p = 0.90 and p = 0.22, respectively), or in the need for the revascularization of the target vessel for ischaemia (p = 0.18 and p = 0.12, respectively). There were two decision-analytic models: the base-case scenario used 1-year follow-up data from the RCT; and a sensitivity analysis used 3-year follow-up data. Resource use was primarily drawn from this RCT. Health-related quality-of-life (HR-QOL) estimates were drawn from a UK cohort study. Both models evaluated the incremental costs and outcomes of bivalirudin compared with heparin plus GPI for patients with STEMI intended for PPCI. The analysis adopted a UK NHS perspective over a lifetime horizon. Unit costs were based on year 2009-2010 prices. The model adopted a decision-tree structure to reflect initial events for the initial period (stroke, repeat MI, minor/major bleeding events, repeat revascularization and death) and a two-state Markov component to simulate longer-term survival. The economic analysis suggested that bivalirudin is expected to dominate the heparin plus GPI strategy. This finding was consistent across the probabilistic sensitivity analysis and the vast majority of deterministic sensitivity analyses undertaken. Three exceptions to this finding were observed for the following sensitivity analyses: (1) the exclusive use of eptifibatide as the GPI (incremental cost-effectiveness ratio [ICER] = £1,764); (2) the combination of 100 % eptifibatide use, 100 % radial arterial access and no differential length between strategies for initial hospital stay (ICER = £4,106); and (3) a longer length of ward stay (increase of 0.33 days) for the initial hospitalization (ICER = £415). The Appraisal Committee (AC) gave a positive recommendation for bivalirudin for the treatment of adults with STEMI undergoing PPCI.

Adult, Antithrombins/adverse effects, Decision Support Techniques, Decision Trees, Drug Industry, Heparin/administration & dosage, Hirudins/adverse effects, Humans, Myocardial Infarction/physiopathology, Peptide Fragments/adverse effects, Percutaneous Coronary Intervention/methods, Platelet Aggregation Inhibitors/administration & dosage, Quality of Life, Randomized Controlled Trials as Topic, Recombinant Proteins/adverse effects, United Kingdom
1170-7690
269-275
Simpson, E L
486027fb-f237-4731-a26a-d52ef9f4760e
Fitzgerald, P
6c86bc21-3767-41c2-a619-a101e7d86118
Evans, P
2d2d377d-ba6e-4a93-9ed9-5a90ce029570
Tappenden, P
c61d68ca-0c6a-4701-87ad-f2e75fd578cb
Kalita, N
da42f168-a3cc-44c9-bafb-2801ff57914b
Reckless, J P D
927d6043-2535-4b53-b51e-e89199fc8cda
Bakhai, A
90d1e6f1-b6f2-44e9-8935-cae8a09eca9a
Simpson, E L
486027fb-f237-4731-a26a-d52ef9f4760e
Fitzgerald, P
6c86bc21-3767-41c2-a619-a101e7d86118
Evans, P
2d2d377d-ba6e-4a93-9ed9-5a90ce029570
Tappenden, P
c61d68ca-0c6a-4701-87ad-f2e75fd578cb
Kalita, N
da42f168-a3cc-44c9-bafb-2801ff57914b
Reckless, J P D
927d6043-2535-4b53-b51e-e89199fc8cda
Bakhai, A
90d1e6f1-b6f2-44e9-8935-cae8a09eca9a

Simpson, E L, Fitzgerald, P, Evans, P, Tappenden, P, Kalita, N, Reckless, J P D and Bakhai, A (2013) Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE Single Technology Appraisal. PharmacoEconomics, 31 (4), 269-275. (doi:10.1007/s40273-013-0036-7).

Record type: Review

Abstract

The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer (The Medicines Company) of bivalirudin to submit evidence for its clinical and cost effectiveness within its licensed indication for the treatment of adults with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PPCI), as part of NICE's single technology appraisal (STA) process. The School of Health and Related Research (ScHARR) at the University of Sheffield was commissioned to act as the Evidence Review Group (ERG), which produced a review of the evidence within the manufacturer's submission to NICE. This article describes the manufacturer's submission, the ERG review and NICE's subsequent decisions. The main evidence was derived from one randomized controlled trial (RCT) of STEMI patients intended for PPCI, comparing bivalirudin with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors (GPIs). Bivalirudin was associated with a significant reduction in cardiac mortality at 30 days (p = 0.03) and at 1-year follow-up (p = 0.005), and a significant reduction in major bleeding at 30 days (p < 0.001) and 1 year (p < 0.0001), compared with heparin plus GPI. Stent thrombosis up to 24 hours following PPCI was significantly (p < 0.001) more common with bivalirudin. However, there was no significant treatment effect for stent thrombosis from 1 to 30 days (p = 0.28), or at 1-year follow-up (p = 0.53). There were no significant treatment group differences at 30 days and at 1 year in stroke (p = 0.68 and p = 0.99, respectively), in myocardial infarction [MI] (p = 0.90 and p = 0.22, respectively), or in the need for the revascularization of the target vessel for ischaemia (p = 0.18 and p = 0.12, respectively). There were two decision-analytic models: the base-case scenario used 1-year follow-up data from the RCT; and a sensitivity analysis used 3-year follow-up data. Resource use was primarily drawn from this RCT. Health-related quality-of-life (HR-QOL) estimates were drawn from a UK cohort study. Both models evaluated the incremental costs and outcomes of bivalirudin compared with heparin plus GPI for patients with STEMI intended for PPCI. The analysis adopted a UK NHS perspective over a lifetime horizon. Unit costs were based on year 2009-2010 prices. The model adopted a decision-tree structure to reflect initial events for the initial period (stroke, repeat MI, minor/major bleeding events, repeat revascularization and death) and a two-state Markov component to simulate longer-term survival. The economic analysis suggested that bivalirudin is expected to dominate the heparin plus GPI strategy. This finding was consistent across the probabilistic sensitivity analysis and the vast majority of deterministic sensitivity analyses undertaken. Three exceptions to this finding were observed for the following sensitivity analyses: (1) the exclusive use of eptifibatide as the GPI (incremental cost-effectiveness ratio [ICER] = £1,764); (2) the combination of 100 % eptifibatide use, 100 % radial arterial access and no differential length between strategies for initial hospital stay (ICER = £4,106); and (3) a longer length of ward stay (increase of 0.33 days) for the initial hospitalization (ICER = £415). The Appraisal Committee (AC) gave a positive recommendation for bivalirudin for the treatment of adults with STEMI undergoing PPCI.

This record has no associated files available for download.

More information

e-pub ahead of print date: 20 March 2013
Published date: April 2013
Keywords: Adult, Antithrombins/adverse effects, Decision Support Techniques, Decision Trees, Drug Industry, Heparin/administration & dosage, Hirudins/adverse effects, Humans, Myocardial Infarction/physiopathology, Peptide Fragments/adverse effects, Percutaneous Coronary Intervention/methods, Platelet Aggregation Inhibitors/administration & dosage, Quality of Life, Randomized Controlled Trials as Topic, Recombinant Proteins/adverse effects, United Kingdom

Identifiers

Local EPrints ID: 438607
URI: http://eprints.soton.ac.uk/id/eprint/438607
ISSN: 1170-7690
PURE UUID: 04764bb8-3c43-401b-a429-bc295a22efd2
ORCID for N Kalita: ORCID iD orcid.org/0000-0002-0973-0160

Catalogue record

Date deposited: 18 Mar 2020 17:32
Last modified: 17 Mar 2024 03:34

Export record

Altmetrics

Contributors

Author: E L Simpson
Author: P Fitzgerald
Author: P Evans
Author: P Tappenden
Author: N Kalita ORCID iD
Author: J P D Reckless
Author: A Bakhai

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×